JP2024525805A5 - - Google Patents

Info

Publication number
JP2024525805A5
JP2024525805A5 JP2024502082A JP2024502082A JP2024525805A5 JP 2024525805 A5 JP2024525805 A5 JP 2024525805A5 JP 2024502082 A JP2024502082 A JP 2024502082A JP 2024502082 A JP2024502082 A JP 2024502082A JP 2024525805 A5 JP2024525805 A5 JP 2024525805A5
Authority
JP
Japan
Prior art keywords
peptide
composition according
pharmaceutically acceptable
acceptable salt
visual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024502082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525805A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/036830 external-priority patent/WO2023287794A2/en
Publication of JP2024525805A publication Critical patent/JP2024525805A/ja
Publication of JP2024525805A5 publication Critical patent/JP2024525805A5/ja
Pending legal-status Critical Current

Links

JP2024502082A 2021-07-13 2022-07-12 眼の疾患および障害における視機能を改善するための方法および組成物 Pending JP2024525805A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163221329P 2021-07-13 2021-07-13
US63/221,329 2021-07-13
US202263336896P 2022-04-29 2022-04-29
US63/336,896 2022-04-29
PCT/US2022/036830 WO2023287794A2 (en) 2021-07-13 2022-07-12 Methods and compositions for improving visual function in ocular diseases and disorders

Publications (2)

Publication Number Publication Date
JP2024525805A JP2024525805A (ja) 2024-07-12
JP2024525805A5 true JP2024525805A5 (https=) 2025-07-17

Family

ID=84919637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502082A Pending JP2024525805A (ja) 2021-07-13 2022-07-12 眼の疾患および障害における視機能を改善するための方法および組成物

Country Status (5)

Country Link
US (2) US20240299488A1 (https=)
EP (1) EP4370208A4 (https=)
JP (1) JP2024525805A (https=)
AU (1) AU2022311780A1 (https=)
WO (1) WO2023287794A2 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010102052A2 (en) * 2009-03-03 2010-09-10 The Regents Of The University Of Michigan Methods of inhibiting photoreceptor apoptosis
US10508134B2 (en) * 2015-05-01 2019-12-17 Onl Therapeutics, Inc. Peptide compositions and methods of use

Similar Documents

Publication Publication Date Title
Hamacher et al. Efficacy and safety levels of preserved and preservative‐free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis
US20130190278A1 (en) Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases
JP7730816B2 (ja) 過剰血管新生に関連する眼疾患を治療する化合物
US11918577B2 (en) Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases
US10413529B2 (en) Methods of inhibiting cataracts and presbyopia
JP6771698B1 (ja) ウルソデオキシコール酸を含有する老視の治療または予防剤
JP7474706B2 (ja) 4-フェニル酪酸を含有する老視の治療または予防剤
US20210299219A1 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
US20190298674A1 (en) Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders
US10736863B2 (en) Methods of inhibiting cataracts and presbyopia
CN114929245A (zh) 用于治疗干性年龄相关性黄斑变性(amd)或继发于干性amd的地图样萎缩的抗c5剂
JP2024525805A5 (https=)
KR20170123502A (ko) 콜라겐 및 색소 상피성 인자를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물
KR102293398B1 (ko) Si를 이용한 망막 변성 개 동물 모델의 제조방법 및 이를 이용한 망막 변성 동물 모델
JP2014510115A (ja) 初期の緑内障における正常な視覚機能を回復するpacap(下垂体アデニル酸シクラーゼ活性化ポリペプチド)に基づく眼科用製剤
CN117731662A (zh) 一种胆碱能受体拮抗剂在预防近视中的应用及制备方法
WO2025036488A9 (en) Methods of treating age-related macular degeneration and diabetic macular edema
US20030166544A1 (en) Use of ADNP for the treatment of glaucomatous optic neuropathy
US20250134849A1 (en) Pharmaceutical composition for preventing or treating ocular disease comprising enavogliflozin
HK40114204A (zh) 通过靶向过氧化物酶体增殖物激活受体(ppar)信号通路治疗屈光性疾病
CN118873659A (zh) 通过靶向过氧化物酶体增殖物激活受体(ppar)信号通路治疗屈光性疾病
TW202529793A (zh) 生長激素抑制劑的用途、和含有生長激素抑制劑的藥物組合物、製劑、及其裝置
JP2026505378A (ja) 視覚を改善するためのα2アドレナリン作動薬
FRACO et al. A REVIEW OF LEISKE STYLE SEMI‐FLEXIBLE INTRAOCULAR LENSES 1981–1984
JP2007182435A (ja) 角結膜障害治療剤